Engflag

Enfalyte

Quick links to important sections

Enfalyte

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enfalyte

Quick Facts

Property Description
Active Ingredients Sodium Chloride, Potassium Citrate, Sodium Citrate
Form Electrolyte Oral Solution (Liquid, Freezer-pops, Jell Cups)
Pharmacological Class Minerals and Electrolytes; Electrolyte Replacement Solutions
Common Use Restoring fluid and mineral balance
Origin Synthetic Combination Product

What Type of Solution is Enfalyte and How is it Classified?

Enfalyte is primarily classified as an Electrolyte Oral Solution (OES), which falls under the pharmacological category of Minerals and Electrolytes and Electrolyte Replacement Solutions. This product is fundamentally a supportive therapeutic agent administered via the Oral route. Enfalyte, manufactured by Mead Johnson, is commonly positioned to support hydration in infants and children following acute episodes of vomiting or diarrhea, though it is suitable for all ages.

Its purpose is to provide immediate, supportive care by countering the effects of acute fluid loss and the resulting electrolyte imbalance. The solution is available in various ready-to-use forms, including a liquid Oral Solution, Freezer-pops, and Jell Cups, offering flexibility in administration.

Composition and Formulation: Electrolytes and Carbohydrates

Enfalyte is a synthetic combination product suspended in an aqueous solution containing precise amounts of mineral salts. The active ingredients include Sodium Chloride, Potassium Citrate, and Sodium Citrate, which supply the essential electrolytes: sodium, potassium, and chloride. The formula also consistently includes a necessary carbohydrate source, typically Corn Syrup Solids, which is critical for its function.

The rationale for this specific formulation aligns with international standards for oral rehydration therapy. The precise combination of sodium and glucose is used because it maximizes the rate at which water and minerals are absorbed across the intestinal wall. This principle is clinically recognized for ensuring the solution supports efficient fluid restoration. Furthermore, the solution is characterized by its low osmolality, a specific low concentration that promotes the swift, effective transfer of water from the digestive tract into the bloodstream, a key differentiating feature from non-therapeutic beverages.

Understanding the General Purpose of Enfalyte

The overall, non-specific therapeutic purpose of Enfalyte is centered on hydration restoration and the correction of fluid and mineral imbalance. By directly replacing the essential electrolytes lost during illness, the product helps stabilize the patient’s body volume and supports the continuation of normal physiological processes. This restorative action provides immediate and non-invasive support, ensuring the effective absorption of fluids and minerals to mitigate the physiological consequences of rapid fluid depletion.

What side effects are possible with Enfalyte?

Possible Side Effects and Safety Information

The safety profile for Enfalyte, an oral electrolyte solution, is primarily based on officially documented risks of misuse, underlying conditions, and adverse reactions related to fluid and electrolyte balance.

Serious Adverse Reactions

Serious adverse reactions require immediate medical attention and are typically signs of severe electrolyte imbalance or an allergic reaction. These reactions include:

  • Signs of severe fluid/electrolyte problems: This encompasses symptoms such as seizures, confusion, severe dizziness, passing out, muscle twitching, or changes in heart rhythm (e.g., fast heartbeat).
  • Signs of an allergic reaction: Documented symptoms include rash, hives, swelling of the face, tongue, or throat, or difficulty breathing.

Common and Expected Effects

Commonly reported effects are related to the gastrointestinal system and include mild nausea or vomiting, which may often be managed by consuming the solution in small, slow sips.

Safety-Related Restrictions and Limitations

The official safety documentation defines key restrictions and situations where use requires particular caution or is contraindicated:

  • Method of Administration: The product is strictly Not for parenteral (I.V.) use.
  • Mixing: It should not be mixed with infant formula, milk, fruit juices, or other electrolyte-containing liquids, as this can alter the electrolyte content and safety profile.
  • Contraindications: Use is restricted in patients with conditions such as intestinal blockage, a perforation in the bowel, or severe, persistent vomiting that prevents fluid retention.

Population-Specific Considerations

  • Infants: The solution should not be given to a child less than 1 year of age without first consulting a healthcare professional.
  • Pregnancy/Lactation: Use during pregnancy or while breastfeeding requires discussion with a doctor to weigh the potential benefits and risks.
  • Monitoring: If symptoms of dehydration worsen or if fever or severe vomiting/diarrhea persists beyond 24 hours, immediate medical advice must be sought.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for this product as arising from exceeding the recommended dose, which may lead to significant systemic and neurological signs.

System Affected (As Stated in Official Labeling) Documented Overdose Manifestations
Fluid and Electrolyte Balance Electrolyte disturbances, oedema (swelling)
Central Nervous System Convulsions (seizures), hypernoia (excessive mental activity)
Gastrointestinal System Nausea, vomiting, diarrhea

These symptoms represent a serious deviation from normal physiological function. The official guidance requires immediate medical attention if any of these manifestations occur or if an overdose is suspected. For the most serious symptoms, such as passing out or trouble breathing, the regulatory text directs users to call 911 (or the local emergency number) immediately. For other instances of suspected overdose, contacting a poison control center is advised as the next step. The presence of convulsions is specifically noted as a potential severe consequence that warrants urgent professional intervention.

Therapeutic Uses of Enfalyte

What Enfalyte Treats

Enfalyte is an oral rehydration solution (ORS) formulated to replace water and essential electrolytes in individuals experiencing dehydration. It is primarily used to manage fluid loss associated with various conditions that disrupt the body's natural balance of minerals and hydration.

Management of Diarrhea and Vomiting

The most common application of Enfalyte is for the management of mild to moderate dehydration resulting from acute diarrhea or vomiting. These conditions can cause the body to lose fluids and salts faster than they can be replenished through a regular diet. Enfalyte provides a specific concentration of glucose and electrolytes to facilitate efficient absorption through the intestinal wall.

Restoration of Electrolyte Balance

Proper physiological function depends on a precise balance of electrolytes, including sodium, potassium, and chloride. Enfalyte is designed to restore these specific minerals when they are depleted. Unlike plain water or sugary beverages, which may not contain the correct proportions of salts, this solution aims to maintain the osmotic balance necessary for cellular function.

Benefits of Oral Rehydration

  • Efficient Absorption: The ratio of carbohydrate to sodium in the solution is designed to optimize the transport of water into the bloodstream.
  • Prevention of Complications: By addressing fluid loss early, the solution helps prevent the progression of mild dehydration into more severe states that might require medical intervention.
  • Suitability: The formulation is designed to be well-tolerated by both children and adults who require a clear liquid to maintain hydration when solid foods cannot be consumed or retained.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Enfalyte?

This section describes the officially documented population eligibility and non-eligibility rules for Enfalyte, based strictly on government-approved product labeling.

Absolute Contraindications

Enfalyte must not be used by individuals with certain pre-existing conditions, as defined in regulatory labeling:

  • A known allergy or hypersensitivity to any of the solution's ingredients.
  • Any patient with a pre-existing blockage in the intestines (gastrointestinal obstruction).
  • Any patient with a perforation (tear or hole) in the bowel.
  • The product is strictly Not for parenteral (I.V.) use; it is restricted to oral use.

Age-Group Eligibility and Conditional Use

Age Group Eligibility Status
Infants and Toddlers (Under 2 years) Use requires consultation with a doctor before administration.
Children (2 years and older) and Adults Approved for use under standard labeled conditions.

Use is conditional and requires immediate medical consultation if symptoms such as vomiting or fever is present, or if diarrhea continues beyond 24 hours. Pregnant or breastfeeding individuals must consult their doctor to discuss the benefits and risks of using the solution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Enfalyte is an Oral Electrolyte Solution, and its officially documented interaction profile is focused on maintaining the product's precise formulation and electrolyte balance.

Administration and Composition Restrictions

Regulatory warnings outline mandatory administration prohibitions, which are official constraints against combining the solution with certain fluids. The product must not be mixed with infant formula, milk, fruit juices, or other electrolyte-containing liquids.

Pharmacodynamic Interactions

Interactions documented in regulatory labeling primarily involve a pharmacodynamic additive effect. Co-administration with mineral supplements, specifically those containing electrolytes such as potassium or sodium, can result in an increased total systemic load of these minerals. This interaction increases the risk of electrolyte imbalance (hyperkalemia or hypernatremia) beyond the formula's intended levels.

Systemic Exposure Modification

These interactions are classified as resulting in systemic exposure modification. Mixing the solution with prohibited liquids alters the intended osmolality and concentration profile of the administered electrolytes (sodium, potassium). This unintended change in concentration modifies the patient's exposure profile, disrupting the solution's therapeutic delivery as defined by the regulatory formulation.

Mechanism of Action

Co-Transport of Sodium and Water

The fundamental action involves the Sodium-Glucose Linked Transporter 1 (SGLT1) protein, situated on the brush border of small intestine epithelial cells. The co-presence of glucose and sodium drives the coupled movement of both solutes from the intestinal lumen into the cell. This process, defined as secondary active transport, establishes a localized osmotic gradient. This gradient is necessary for the passive absorption of water across the intestinal barrier, which consequently increases fluid movement into the general circulation.

Electrolyte and Acid-Base Stabilization

Enfalyte provides essential electrolytes (sodium, potassium, chloride) and a citrate base precursor, absorbed through specific transport channels in the gut. The absorption of these ions is vital for maintaining normal cellular function and neuromuscular excitability. Following absorption, the citrate precursor is metabolized systemically into bicarbonate, which contributes to the regulation of systemic pH.

Dosage and Administration Information

How to Use Enfalyte: Official Administration Guidelines

Enfalyte is an Oral Electrolyte Solution strictly intended for oral administration and is not for intravenous (I.V.) use. The product is supplied as a ready-to-use liquid and in frozen forms, requiring no dilution or mixing with other fluids.

Dosing and Frequency

Administration is structured around replacing acute fluid loss over a short-term period. For the initial replacement of mild to moderate deficits, official regimens often cite administering 50 mL to 100 mL per kilogram of body weight over 2 to 4 hours. The solution is typically offered to children age 2 years and older and adults in small, frequent sips, often suggested every 15 to 30 minutes, and increased as tolerated. Total daily intake may range from 100 mL to 150 mL per kilogram of body weight, adjusted for ongoing losses.

Preparation and Handling Constraints

The solution must be administered as supplied; it is strictly prohibited to add water, dilute, or mix it with beverages such as milk, infant formula, or fruit juices. For administration to infants and toddlers under 2 years of age, a doctor’s consultation is required. The product should not be warmed using a microwave oven. Once opened, the solution must be refrigerated and used within 24 hours, or discarded within one hour if feeding has begun. If diarrhea or fever persists beyond 24 hours, medical advice should be sought.

Recent Clinical Evidence

Research evidence / Overview of studies

Efficacy Research Overview

Research has investigated the use of this oral electrolyte solution, often within the context of Oral Rehydration Therapy (ORT), which is generally used to manage fluid and electrolyte loss due to diarrhea and vomiting. Studies have examined whether the product affects hydration status in pediatric patients with acute gastroenteritis.

  • Primary outcomes: These studies generally measure overall treatment failure, which is a composite outcome that may include the need for intravenous (IV) rehydration, unscheduled follow-up visits, or persistent dehydration.
  • Comparative Studies: One randomized controlled trial compared an electrolyte maintenance solution (such as Enfalyte) to dilute apple juice followed by preferred fluids in children with minimal dehydration. This research measured the time to symptom change and the rate of subsequent unscheduled healthcare visits.

Tolerability and Pharmacokinetics

Clinical studies provide information on the tolerability profile of oral rehydration solutions (ORS). Tolerability often relates to factors like palatability, which can influence adherence, as well as the occurrence of common gastrointestinal adverse events like nausea or vomiting.

  • Osmolality: The formulation's low osmolality (a measure of concentration) is designed to support the absorption of water and electrolytes in the gastrointestinal tract, a core mechanism of ORT.
  • Renal Function: The pharmacokinetics and adverse event reporting related to electrolyte replacement were studied in participants across different patient groups, including those with varying degrees of renal function.

Frequently Asked Questions (FAQ)

Common questions about Enfalyte (FAQ)

Q: What is Enfalyte?

A: Enfalyte is an oral electrolyte solution used to help prevent dehydration in infants and children. It is specifically formulated to replace water and important electrolytes (like sodium and potassium) that are lost due to vomiting or diarrhea.

Q: How do I prepare Enfalyte?

A: Enfalyte is typically sold as a ready-to-use liquid solution, meaning no preparation or mixing with water is required. It should be given at room temperature or chilled, depending on the child's preference, unless a healthcare provider advises otherwise. Do not add extra water or dilute the solution, as this can change the concentration of the electrolytes.

Q: How much Enfalyte should I give my child?

A: The amount of Enfalyte to give your child depends on their age, weight, and the severity of the dehydration. Always follow the instructions provided by your child's pediatrician or healthcare provider. General guidelines often suggest:

  • Small, frequent sips (e.g., a few teaspoons every 5–10 minutes) for the first hour.
  • Gradually increasing the volume as the child tolerates it.

Never exceed the volume recommended by a healthcare professional.

Q: How long can I use Enfalyte for?

A: Enfalyte is typically used for a short period (usually 1 to 2 days) or until the symptoms of vomiting and diarrhea have stopped and the child is able to tolerate their regular diet, such as breast milk, formula, or solid foods. Consult a healthcare provider if dehydration symptoms continue or worsen after 24–48 hours of use.

Q: Should I give my child food while they are drinking Enfalyte?

A: In many cases, a child can continue to receive some level of feeding (like a regular formula or breast milk) alongside the use of Enfalyte. The goal is to return to a normal diet quickly. However, this depends heavily on the child's condition and the specific advice of a pediatrician. For a severe episode, a provider may recommend only the electrolyte solution for a few hours before reintroducing other foods.

Q: Does Enfalyte contain milk or lactose?

A: No, Enfalyte does not contain milk or lactose. It is a clear, colorless or lightly tinted electrolyte solution that is generally well-tolerated by children, including those with lactose intolerance or milk allergies. The primary ingredients are water, sugar (dextrose), and essential electrolytes.

Q: What is the difference between Enfalyte and PediaLyte?

A: Both Enfalyte and PediaLyte are brand-name oral electrolyte solutions designed to prevent and treat mild to moderate dehydration in children. They share a similar basic function and composition, replacing lost water and key electrolytes. The primary difference is the manufacturer and minor variations in flavoring and exact electrolyte concentration, though both meet similar medical standards for rehydration. They are generally considered interchangeable.

How should Enfalyte be stored and disposed of?

How to Store and Dispose of Enfalyte?

The official storage and disposal requirements for Enfalyte Electrolyte Oral Solution are regulated to ensure product stability and safety.

Storage Requirements

Condition Requirement
Unopened (Temperature) Store at room temperature or refrigerate (35-40 F / 2-4 C).
Prohibited Do not freeze. Avoid excessive heat and prolonged light exposure.
Opened (Shelf-Life) Must be refrigerated and used within 24 hours. Discard any remainder after one hour of starting a feeding.
Packaging Do not use if the cap ring is broken or missing; do not warm in a microwave oven.

Disposal and Safety

To dispose of unused or expired Enfalyte, it must not be poured into wastewater (sinks or toilets) or placed in household garbage. Official guidance requires asking a pharmacist for instructions on proper disposal. The product must always be stored out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Enfalyte found in:

A-Z Index: